Ariad Pharmaceuticals
E387618
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ariad Pharmaceuticals canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3803132 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ariad Pharmaceuticals Context triple: [Stuart L. Schreiber, coFounderOf, Ariad Pharmaceuticals]
-
A.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
E.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ariad Pharmaceuticals Target entity description: Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
A.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Idera, Inc.
Idera, Inc. is a software company best known for its database management, performance monitoring, and developer tools used by IT professionals and enterprises.
-
C.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
D.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
E.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
- F. None of above. chosen
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| acquiredBy | Takeda Pharmaceutical Company ⓘ |
| acquisitionAnnouncementDate | 2017-01 ⓘ |
| acquisitionCompletionDate | 2017-02 ⓘ |
| acquisitionValueUSD | 5200000000 ⓘ |
| brigatinibBrandName | Alunbrig ⓘ |
| brigatinibIndication | ALK-positive non-small cell lung cancer ⓘ |
| businessModel | research and development of small-molecule drugs ⓘ |
| collaboration | Merck & Co. ⓘ |
| collaborationType | drug discovery and development ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| defunctReason | acquisition by Takeda Pharmaceutical Company ⓘ |
| employeeType | scientists and researchers ⓘ |
| focus |
targeted cancer therapies
ⓘ
treatments for serious diseases ⓘ |
| foundedBy | Harvey J. Berger ⓘ |
| foundingDate | 1991 ⓘ |
| headquartersLocation | Cambridge, Massachusetts ⓘ |
| IclusigRegulatoryEvent |
label updates with safety warnings
ⓘ
temporary marketing suspension in 2013 due to safety concerns ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyPerson |
Harvey J. Berger
ⓘ
Paris Panayiotopoulos ⓘ |
| keyPersonRole | Chief Executive Officer ⓘ |
| location |
Massachusetts
ⓘ
United States ⓘ
linked to:
United States of America
|
| notableProduct |
brigatinib
ⓘ
ponatinib ⓘ |
| Paris PanayiotopoulosRole | Chief Executive Officer ⓘ |
| ponatinibBrandName | Iclusig ⓘ |
| ponatinibIndication |
Philadelphia chromosome–positive acute lymphoblastic leukemia
ⓘ
chronic myeloid leukemia ⓘ |
| regulatoryBodyInteraction |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| regulatoryRegion |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| researchArea |
oncology
ⓘ
signal transduction inhibitors ⓘ tyrosine kinase inhibitors ⓘ |
| status | defunct ⓘ |
| therapeuticClass | oncology therapeutics ⓘ |
| tickerSymbol | ARIA ⓘ |
| tradedOn | NASDAQ ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ariad Pharmaceuticals Description of subject: Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.